Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
LBRX · Why this verdict
Why LB Pharmaceuticals (LBRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
LB Pharmaceuticals is a pre-revenue biotech with its value tied to a single pipeline asset (LB-102), a $10M insider purchase and 30% upside to the analyst target, offset by three straight EPS misses, cash burn and 22% short interest.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business depends on one pipeline candidate, LB-102, flagged as a high-severity concentration risk, with zero revenue in every recent quarter. Bear case | LB-102 clinical milestones should be met on schedule over the next 12 months. | ↓Deteriorating |
| CounterA single failed trial or delay could erase most of the value, and a pre-revenue company has no other income to cushion it. | ||
Quality scores 1.6/10 with negative free cash flow and all margins at zero, and short interest is 22%. Quality breakdown | Cash runway should cover operations through the next 12 months without dilutive financing. | →Stable |
| CounterA high short interest alongside strong accumulation can produce sharp squeezes, but also signals sophisticated investors betting on failure. | ||
Insiders bought $9,999,974 of stock in 90 days (0.800% of market cap) with no sales, and institutions are accumulating. Insider | Insider net buying should stay positive and institutional ownership should rise over the next 12 months. | ↓Deteriorating |
| CounterA single purchase may reflect one large holder's participation in a financing, which is not necessarily management conviction. | ||
EPS missed in all 3 reported quarters, including -$1.71 against a -$0.80 estimate in August 2026, with an average surprise of -91%. Last 4 quarters | Quarterly EPS loss should narrow to $0.80 or less per share over the next 12 months. | ↓Deteriorating |
| CounterWidening losses may reflect growing trial spending, which is expected for a company advancing a late-stage asset. | ||
The $50.46 analyst target is 30.3% above the $38.73 price against 14.5% downside to the $36.02 stop, supported by an analyst-rating score of 8.3/10. Analyst target | Price should move toward $50.46 as clinical data are released over the next 12 months. | ↓Deteriorating |
| CounterBiotech analyst targets depend on trial success probabilities and can be cut sharply on any negative readout. | ||
The business depends on one pipeline candidate, LB-102, flagged as a high-severity concentration risk, with zero revenue in every recent quarter.
↓DeterioratingBear case
- Expectation
- LB-102 clinical milestones should be met on schedule over the next 12 months.
CounterA single failed trial or delay could erase most of the value, and a pre-revenue company has no other income to cushion it.
Quality scores 1.6/10 with negative free cash flow and all margins at zero, and short interest is 22%.
→StableQuality breakdown
- Expectation
- Cash runway should cover operations through the next 12 months without dilutive financing.
CounterA high short interest alongside strong accumulation can produce sharp squeezes, but also signals sophisticated investors betting on failure.
Insiders bought $9,999,974 of stock in 90 days (0.800% of market cap) with no sales, and institutions are accumulating.
↓DeterioratingInsider
- Expectation
- Insider net buying should stay positive and institutional ownership should rise over the next 12 months.
CounterA single purchase may reflect one large holder's participation in a financing, which is not necessarily management conviction.
EPS missed in all 3 reported quarters, including -$1.71 against a -$0.80 estimate in August 2026, with an average surprise of -91%.
↓DeterioratingLast 4 quarters
- Expectation
- Quarterly EPS loss should narrow to $0.80 or less per share over the next 12 months.
CounterWidening losses may reflect growing trial spending, which is expected for a company advancing a late-stage asset.
The $50.46 analyst target is 30.3% above the $38.73 price against 14.5% downside to the $36.02 stop, supported by an analyst-rating score of 8.3/10.
↓DeterioratingAnalyst target
- Expectation
- Price should move toward $50.46 as clinical data are released over the next 12 months.
CounterBiotech analyst targets depend on trial success probabilities and can be cut sharply on any negative readout.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 8.3 |
| Price target | 9.3 |
- ▸Analyst upside: 43%
Insider
6.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 8.3 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.0 |
| quality rank | 2.6 |
| growth rank | 5.0 |
Technical
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.5 |
| support resistance | 1.0 |
| 52w position | 6.2 |
Risk (lower is worse)
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.5 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.8 |
| debt equity | 9.9 |
- ▸High short interest justified: 20%
- ▸Elevated put/call: 3.75
- ▸High IV: 75%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 0B/2M
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.4>=5.5
- ASYMMETRY:1.6>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
1.60
Upside
+24.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.3B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Sentiment at 8.0 and asymmetric R:R of 1.60.
The strongest dimensions are Sentiment at 8.0, Value at 7.5, and Insider at 6.8; the weakest are Quality at 1.6, Risk (lower is worse) at 2.0, and Technical at 2.9. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 1.60 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Pipeline Asset
Trip ifLB-102 trial readout is delayed by more than 6 months from the current guided timeline.
- P2Large Insider Purchase
Trip ifInsider net purchases over 90 days fall to less than $0 (net selling).
- P3Consecutive Earnings Misses
Trip ifQuarterly EPS loss exceeds $2.00 per share from the current $1.71.
- P4Analyst Target Upside
Trip ifShare price falls below the $36.02 stop-loss level.
- P5Cash Burn And Short Interest
Trip ifShort interest rises above 30% from the current 22%.